Novartis, Ionis Heart Drug Misses Phase 3 Goal Despite Cutting Lp(a)
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.
/ 4 items
#RPRX↓
Teva’s Anti-IL-15 Antibody Meets Main Goal in Celiac Disease Study
Teva’s TEV ’408 met its Phase 2a primary endpoint in celiac disease, limiting gluten-induced intestinal damage after one subcutaneous dose.
Royalty Pharma Completes $240M Deal for Full Evrysdi Royalty Rights
Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.
Denali and Royalty Pharma Strike $275M Deal for Hunter Syndrome Treatment
Denali Therapeutics secures $275 million from Royalty Pharma for tividenofusp alfa, a promising therapy for Hunter syndrome awaiting FDA approval in April 2026.